Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.

Bird flu has emerged as a critical public health concern in California, with Governor Gavin Newsom declaring a state of ...

Let's explore two healthcare sector dividend stocks that could make a fantastic addition to your ... Pfizer has struggled in ...

Vaxcyte (PCVX) has received a new Buy rating, initiated by Goldman Sachs analyst, Chris Shibutani.Pick the best stocks and maximize your ...

Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

After falling off their perch in the last few months of 2024, European healthcare stocks head into a new year facing the ...

Argus downgraded Moderna (MRNA) to Hold from Buy without a price target The firm sees limited upside for the stock over the next 12 months as ...

Thermo Fisher perfectly rode the tidal wave of demand for health care that came during the pandemic. The company experienced ...

Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the ...